Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $5.83.

SRTS has been the topic of a number of analyst reports. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Lake Street Capital lowered their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th.

Insider Transactions at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta acquired 27,304 shares of the stock in a transaction dated Monday, August 31st. The stock was acquired at an average cost of $3.54 per share, with a total value of $96,656.16. Following the transaction, the director owned 294,784 shares in the company, valued at $1,043,535.36. The trade was a 10.21% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders bought 120,171 shares of company stock worth $405,230. 10.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of SRTS. BlackRock Inc. purchased a new stake in Sensus Healthcare in the second quarter valued at $252,000. Bank of New York Mellon Corp acquired a new position in Sensus Healthcare in the second quarter valued at $303,000. EP Wealth Advisors LLC acquired a new position in Sensus Healthcare in the second quarter valued at $49,000. Finally, North Star Investment Management Corp. purchased a new position in shares of Sensus Healthcare during the first quarter worth about $500,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Stock Performance

SRTS stock opened at $2.93 on Tuesday. The company’s 50 day moving average price is $3.11 and its 200 day moving average price is $3.29. The firm has a market capitalization of $48.23 million, a price-to-earnings ratio of -3.12 and a beta of 1.18. Sensus Healthcare has a fifty-two week low of $2.66 and a fifty-two week high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $4.60 million.

About Sensus Healthcare

Sensus Healthcare, Inc (NASDAQ: SRTS) develops and markets non-invasive medical devices for dermatology and oncology. The company’s primary focus is superficial radiation therapy, a low-energy X-ray treatment designed to treat conditions affecting or located near the surface of the skin.

Its product portfolio includes the SRT-100 system and related platforms, which are used primarily in the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as keloid scars.